New 'schizophrenia gene' prompts researchers to test potential drug target

Oct 27, 2009

Johns Hopkins scientists report having used a commercially available drug to successfully "rescue" animal brain cells that they had intentionally damaged by manipulating a newly discovered gene that links susceptibility genes for schizophrenia and autism.

The rescue, described as "surprisingly complete" by the researchers, was accomplished with rapamycin, a drug known to act on a called mTOR whose role involves the production of other proteins. The idea to test this drug's effectiveness at rescuing impaired nerve cells occurred to the team as a result of having discovered a new gene that appears to act in concert with two previously identified susceptibility , one of which is involved in the activation of the protein mTOR. This piecing together of multiple genes adds support for the idea that susceptibility to schizophrenia and may have common genetic fingerprints, according to the researchers.

In a report on the work published in the Sept. 24 issue of the journal Neuron, the scientists are careful to say that the genes in question are not the cause of schizophrenia or any other brain/mind disorder in humans. However, these genes do appear to serve as a blueprint for proteins that consistently pop up in a range of mental illnesses in people.

The newfound gene, dubbed KIAA1212, serves as a bridge linking two schizophrenia genes: DISC1 and AKT. Suspecting KIAA1212 as one of many potential binding partners interacting with DISC1, whose name is an acronym for "Disrupted-in-Schizophrenia," the researchers genetically shut down the production of DISC1 proteins in newly born in the hippocampus region of an adult mouse brain. The hippocampus contains a niche where native give rise to fully developed new neurons. The idea was to deliberately cause these cells to malfunction and then watch what happened.

The scientists found that the newborn neurons were most noticeably defective 14 days after DISC1 suppression and that they were defective in a variety of ways. By manipulating AKT production, or altering KIAA1212, they discovered the very same abnormalities as with DISC1 deficiency, concluding that KIAA1212 is in the same signaling pathway as DISC1 and AKT.

Because mTOR is a well-known downstream effector of AKT, they treated the adult mice harboring those abnormal neurons with rapamycin, a drug known to alleviate the effects of a faulty AKT pathway. It effectively "rescued" the neurons from their defects.

"Our discoveries give us more of the information we need to understand the function of genes associated with psychological diseases," says Guo-li Ming, M.D., Ph.D., an associate professor of neurology and neuroscience in the Institute for Cell Engineering at the Johns Hopkins University School of Medicine. "The next step is to create a good animal model that would allow us to test whether candidate drugs will reverse not only the irregularities of with deficiency of these genes, but also behaviors."

The new neurons with alterations of , KIAA1212 or AKT in the brains of the Rapamycin-treated mice developed normally, says Hongjun Song, Ph.D., an associate professor of Neurology in the Institute for Cell Engineering at the Johns Hopkins University School of Medicine, who collaborated in the research. "What was amazing to us is how potent the drug is, at least on the cellular level," he says. "A number of the neurons' developmental defects — from enlarged cell size to the misplacement of cell localization and abnormal neuronal processes involved in receiving and sending messages — were corrected by this one drug."

More information: Neuron: www.cell.com/neuron/

Source: Johns Hopkins Medical Institutions

Explore further: Lost memories might be able to be restored, new study indicates

add to favorites email to friend print save as pdf

Related Stories

Normal role for schizophrenia risk gene identified

Sep 07, 2007

How the gene that has been pegged as a major risk factor for schizophrenia and other mood disorders that affect millions of Americans contributes to these diseases remains unclear. However, the results of a new study by Hopkins ...

Hopkins team develops first mouse model of schizophrenia

Jul 30, 2007

Johns Hopkins researchers have genetically engineered the first mouse that models both the anatomical and behavioral defects of schizophrenia, a complex and debilitating brain disorder that affects over 2 million Americans.

Schizophrenia-linked gene controls the birth of new neurons

Mar 19, 2009

A gene that is arguably the most studied "schizophrenia gene" plays an unanticipated role in the brain: It controls the birth of new neurons in addition to their integration into existing brain circuitry, according to a report ...

A genetic basis for schizophrenia

Jul 21, 2009

Schizophrenia is a severely debilitating psychiatric disease that is thought to have its roots in the development of the nervous system; however, major breakthroughs linking its genetics to diagnosis, prognosis and treatment ...

Recommended for you

Researchers unlock mystery of skin's sensory abilities

Dec 19, 2014

Humans' ability to detect the direction of movement of stimuli in their sensory world is critical to survival. Much of this stimuli detection comes from sight and sound, but little is known about how the ...

Tackling neurotransmission precision

Dec 18, 2014

Behind all motor, sensory and memory functions, calcium ions are in the brain, making those functions possible. Yet neuroscientists do not entirely understand how fast calcium ions reach their targets inside ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.